Pharmaceuticals

Asceniv Market Growth Expected To Reach $4.5 Billion By 2030 At 6.9% CAGR

May 5, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Anticipated Rise In Market Value Of The Asceniv Market During The Forecast Period?

The growth witnessed in the historic period can be attributed to the proven effectiveness of IVIG therapies, coupled with increasing awareness of primary immunodeficiency, the wider adoption of immunoglobulin infusions by hospitals, clinical achievements in infection reduction, and the readily available plasma-derived antibodies.

The anticipated growth during the forecast period is fueled by several factors, including an increase in primary immunodeficiency (PID) diagnosis rates, a transition towards home infusion care models, enhanced plasma supply chain management, the broadening of specialized immunology services, and improved adherence to long-term therapies. Concurrently, significant trends for this period involve the escalating adoption of immunoglobulin replacement therapies, a rise in the identification of primary immunodeficiency disorders, the expansion of prolonged antibody infusion treatments, greater acceptance of home-based immunotherapy, and advancements in infection prevention for immunocompromised patients.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19976&type=smp

Which Strong Drivers Are Impacting The Asceniv Market Growth?

The asceniv market is anticipated to expand, driven by the rising occurrence of respiratory conditions. These conditions encompass illnesses impacting the lungs and airways, from acute infections such as pneumonia to long-term ailments like asthma and COPD. Key contributors to this surge include air pollution, smoking, climate change, an aging global demographic, and heightened vulnerability to infections. Asceniv addresses respiratory ailments by strengthening the immune system through antibodies, thereby assisting those with immune deficiencies or viral respiratory issues in combating infections. For example, the National Institutes of Health, a US government agency, stated in December 2023 that the number of COPD cases is projected to increase by 112 million, totaling 592 million by 2050, representing 9.5% of the eligible demographic. Consequently, the growing prevalence of respiratory diseases is fueling the expansion of the Asceniv market.

What Segment Categories Shape The Asceniv Market Segment Landscape?

The asceniv market covered in this report is segmented –

1) By Indication: Primary Humoral Immunodeficiency, Other Indications

2) By Formulation: Liquid Form, Lyophilized Form

3) By End User: Hospitals, Clinics, Homecare

Which Trends Are Shaping The Asceniv Market?

Companies operating within the asceniv market are concentrating on developing product innovations, such as extended room temperature storage conditions for Asceniv, to boost its stability, improve accessibility, and mitigate storage and transportation challenges. These extended storage conditions for Asceniv signify the ability to keep the product at room temperature for an extended duration without compromising its efficacy or safety. For instance, in March 2024, ADMA Biologics, a US-based biotechnology company, obtained FDA approval for extended room temperature storage conditions for its intravenous immunoglobulin products, ASCENIV and BIVIGAM. Both products can now be stored at room temperature (25°C) for up to four weeks during their 36-month shelf life, enhancing usability and distribution. This modification supports improved inventory management and increases access for healthcare providers, especially in locations with limited refrigeration. ASCENIV is prescribed for treating primary humoral immunodeficiency in adults and adolescents, while BIVIGAM is utilized for various forms of this condition.

Who Are The Companies Operating Across The Asceniv Market Value Chain?

Major companies operating in the asceniv market are ADMA Biologics Inc.

Get The Full Asceniv Market Report:

https://www.thebusinessresearchcompany.com/report/asceniv-global-market-report

Where Is The Asceniv Market Most Concentrated Geographically?

North America was the largest region in the asceniv market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the asceniv market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Asceniv Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/asceniv-global-market-report

Browse Through More Reports Similar to the Global Asceniv Market 2026, By The Business Research Company

Trade Finance Market Report 2026

https://www.thebusinessresearchcompany.com/report/trade-finance-global-market-report

Market Research Services Market Report 2026

https://www.thebusinessresearchcompany.com/report/market-research-services-global-market-report

Data Lake Market Report 2026

https://www.thebusinessresearchcompany.com/report/data-lake-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795